Physician profile
Steven Wolinsky
NPI 1982602405
$4,304.86
in general payments reported to CMS, 2019-2025
37 companies · $550 in 2025
The $550 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $270 · 2021: $563 · 2022: $370 · 2023: $624 · 2024: $879 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,259.13 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $440.63 | 2022-2024 | Sotyktu |
| Pfizer INC. | $291.12 | 2019-2024 | |
| Lilly USA, LLC | $266.48 | 2019-2024 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $255.96 | 2019-2025 | Simponi Aria, Simponi, Tremfya |
| Amgen INC. | $186.22 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $162.64 | 2019-2024 | |
| Almirall LLC | $161.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $152.72 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $95.39 | 2019-2023 | Odomzo, Blu-U |
| Lnhc, INC | $91.10 | 2025 | Zelsuvmi |
| Regeneron Healthcare Solutions, INC. | $89.21 | 2023-2024 | Dupixent |
| Leo Pharma INC. | $88.88 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $72.18 | 2023-2025 | Zoryve |
| Sandoz INC. | $66.71 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $61.71 | 2020-2021 | |
| Genentech USA, INC. | $42.19 | 2019 | |
| Celgene Corporation | $41.46 | 2019 | |
| Galderma Laboratories, L.P. | $41.13 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $40.78 | 2019 | |
| Prugen, INC. Pharmaceuticals | $37.00 | 2019 | |
| Kyowa Kirin, INC. | $36.80 | 2020-2023 | Poteligeo |
| Botanix Sb INC | $36.47 | 2025 | Sofdra |
| Incyte Corporation | $35.66 | 2021-2022 | |
| Ucb, INC. | $29.98 | 2019-2023 | Cimzia |
| Melinta Therapeutics, LLC | $25.59 | 2019 | |
| Promius Pharma LLC | $25.09 | 2019 | |
| Biofrontera INC. | $24.56 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $22.19 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $19.78 | 2024 | Ycanth |
| Journey Medical Corporation | $18.72 | 2022 | |
| Organogenesis INC. | $18.15 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.03 | 2019 | |
| Mayne Pharma Commercial LLC | $13.95 | 2019 | |
| Dermavant Sciences, INC. | $13.71 | 2023 | Vtama |
| Merck Sharp & Dohme LLC | $12.65 | 2019 | |
| Aclaris Therapeutics, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Wolinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.